Literature DB >> 30810119

Accurate and selective quantification of anthrax protective antigen in plasma by immunocapture and isotope dilution mass spectrometry.

Maria I Solano1, Adrian R Woolfitt, Anne E Boyer, Renato C Lins, Katie Isbell, Maribel Gallegos-Candela, Hercules Moura, Carrie L Pierce, John R Barr.   

Abstract

Anthrax protective antigen (83 kDa, PA83) is an essential component of two major binary toxins produced by Bacillus anthracis, lethal toxin (LTx) and edema toxin (ETx). During infection, LTx and ETx contribute to immune collapse, endothelial dysfunction, hemorrhage and high mortality. Following protease cleavage on cell receptors or in circulation, the 20 kDa (PA20) N-terminus is released, activating the 63 kDa (PA63) form which binds lethal factor (LF) and edema factor (EF), facilitating their entry into their cellular targets. Several ELISA-based PA methods previously developed are primarily qualitative or semi-quantitative. Here, we combined protein immunocapture, tryptic digestion and isotope dilution liquid chromatography-mass spectrometry (LC-MS/MS), to develop a highly selective and sensitive method for detection and accurate quantification of total-PA (PA83 + PA63) and PA83. Two tryptic peptides in the 63 kDa region measure total-PA and three in the 20 kDa region measure PA83 alone. Detection limits range from 1.3-2.9 ng mL-1 PA in 100 μL of plasma. Spiked recovery experiments with combinations of PA83, PA63, LF and EF in plasma showed that PA63 and PA83 were quantified accurately against the PA83 standard and that LF and EF did not interfere with accuracy. Applied to a study of inhalation anthrax in rhesus macaques, total-PA suggested triphasic kinetics, similar to that previously observed for LF and EF. This study is the first to report circulating PA83 in inhalation anthrax, typically at less than 4% of the levels of PA63, providing the first evidence that activated PA63 is the primary form of PA throughout infection.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30810119      PMCID: PMC7015108          DOI: 10.1039/c8an02479k

Source DB:  PubMed          Journal:  Analyst        ISSN: 0003-2654            Impact factor:   4.616


  40 in total

1.  Structure of heptameric protective antigen bound to an anthrax toxin receptor: a role for receptor in pH-dependent pore formation.

Authors:  D Borden Lacy; Darran J Wigelsworth; Roman A Melnyk; Stephen C Harrison; R John Collier
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

Review 2.  Anthrax lethal and edema toxins in anthrax pathogenesis.

Authors:  Shihui Liu; Mahtab Moayeri; Stephen H Leppla
Journal:  Trends Microbiol       Date:  2014-03-27       Impact factor: 17.079

3.  Domain flexibility modulates the heterogeneous assembly mechanism of anthrax toxin protective antigen.

Authors:  Geoffrey K Feld; Alexander F Kintzer; Iok I Tang; Katie L Thoren; Bryan A Krantz
Journal:  J Mol Biol       Date:  2011-10-31       Impact factor: 5.469

Review 4.  Anthrax toxin: receptor binding, internalization, pore formation, and translocation.

Authors:  John A T Young; R John Collier
Journal:  Annu Rev Biochem       Date:  2007       Impact factor: 23.643

5.  Serum protease cleavage of Bacillus anthracis protective antigen.

Authors:  J W Ezzell; T G Abshire
Journal:  J Gen Microbiol       Date:  1992-03

6.  Ratio of lethal and edema factors in rabbit systemic anthrax.

Authors:  Federica Dal Molin; Antonio Fasanella; Morena Simonato; Giuliano Garofolo; Cesare Montecucco; Fiorella Tonello
Journal:  Toxicon       Date:  2008-09-05       Impact factor: 3.033

7.  Kinetics of lethal factor and poly-D-glutamic acid antigenemia during inhalation anthrax in rhesus macaques.

Authors:  Anne E Boyer; Conrad P Quinn; Alex R Hoffmaster; Thomas R Kozel; Elke Saile; Chung K Marston; Ann Percival; Brian D Plikaytis; Adrian R Woolfitt; Maribel Gallegos; Patrick Sabourin; Lisa G McWilliams; James L Pirkle; John R Barr
Journal:  Infect Immun       Date:  2009-06-08       Impact factor: 3.441

8.  High-sensitivity MALDI-TOF MS quantification of anthrax lethal toxin for diagnostics and evaluation of medical countermeasures.

Authors:  Anne E Boyer; Maribel Gallegos-Candela; Conrad P Quinn; Adrian R Woolfitt; Judith O Brumlow; Katherine Isbell; Alex R Hoffmaster; Renato C Lins; John R Barr
Journal:  Anal Bioanal Chem       Date:  2015-02-12       Impact factor: 4.142

9.  Validated MALDI-TOF-MS method for anthrax lethal factor provides early diagnosis and evaluation of therapeutics.

Authors:  Maribel Gallegos-Candela; Anne E Boyer; Adrian R Woolfitt; Judy Brumlow; Renato C Lins; Conrad P Quinn; Alex R Hoffmaster; Gabriel Meister; John R Barr
Journal:  Anal Biochem       Date:  2017-12-07       Impact factor: 3.365

10.  Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits.

Authors:  Alfred Corey; Thi-Sau Migone; Sally Bolmer; Michele Fiscella; Chris Ward; Cecil Chen; Gabriel Meister
Journal:  Toxins (Basel)       Date:  2013-01-14       Impact factor: 4.546

View more
  2 in total

1.  Clindamycin Protects Nonhuman Primates Against Inhalational Anthrax But Does Not Enhance Reduction of Circulating Toxin Levels When Combined With Ciprofloxacin.

Authors:  Nicholas J Vietri; Steven A Tobery; Donald J Chabot; Susham Ingavale; Brandon C Somerville; Jeremy A Miller; Chris W Schellhase; Nancy A Twenhafel; David P Fetterer; Christopher K Cote; Christopher P Klimko; Anne E Boyer; Adrian R Woolfitt; John R Barr; Mary E Wright; Arthur M Friedlander
Journal:  J Infect Dis       Date:  2021-02-03       Impact factor: 5.226

Review 2.  Anthrax Toxin Detection: From in Vivo Studies to Diagnostic Applications.

Authors:  Jean-Nicolas Tournier; Clémence Rougeaux
Journal:  Microorganisms       Date:  2020-07-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.